MSB 7.69% $1.19 mesoblast limited

Ann: MSB Annual Financial Results and Operational Progress, page-17

  1. 8 Posts.
    The fact that a commercial team has been built shows me the management team's confidence in the future of some of these trials.

    However, earlier in the presentation, it's been pointed out that there are strategies for building partnerships for the sake of rem-L commercialisation in C-19 ARDS.

    Sounds very promising!

    DYOR, GLTAH
  2. 1,790 Posts.
    lightbulb Created with Sketch. 193
    Col69, you've been onto this for a long time but....

    Still with all the available treatments, mortality for moderate to severe covid Ards still remains at 60 to 80 percent. Rem-l here we come
    Last edited by Jakeo17: 27/08/20
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.